Skip to main content
editorial
. 2021 Oct 6;23(5):e13724. doi: 10.1111/tid.13724

TABLE 1.

Comparison of retrospective observational cohorts of the use of anti‐SARS‐CoV2 monoclonal antibody in solid organ transplant recipients

Study Participants Transplant type Time to mAB therapy ED or hospitalization Deaths Adverse effects
Kutzler et al. 13 18

15 KT

2 LT

1 HrtT

 5 (3–7) from test 4/18 (22.2%)

  • 3 hospitalizations

  • 1 ED visit

 None No infusion reactions Postinfusion

  • 1 HA, fatigue
Dhand et al. 14 10

6 KT

2 LT

1 LK

1 HrtT

 3.3 (1–10) from symptoms None None No infusion reactions Postinfusion

  • 1 pruritis
Jan et al. 15 24 24 KT 4.75 (2.45–7.05) from symptoms 4/24 (16/7%)

  • 2 ICU

 1 No infusion reactions Postinfusion

  • 2 HA

  • 2 Nausea

  • 1 Rash
Yetmar et al. 16 73

41 KT

4 KP

13 LT

11 HrtT

1 HrtL

2 Lung

1 Panc

4 (3–7) from symptoms

75.3% bamlanivimab

24.7% casirivimab–imdevimab

 11/73 (15.1%)

  • 9 hospitalized

  • 1 ICU

 None No infusion reactions Postinfusion

  • 4 fever

  • 2 vomiting

  • 1 nausea

  • 1 rigors

  • 1 rash

  • 1 worsening sinus congestion

Abbreviations: ED, emergency department; HA, headache; HrtT, heart transplant; HrtL, heart liver transplant; KT, kidney transplant; LK, liver transplant; LT, liver transplant; mAB, monoclonal antibody; Panc, pancreas transplant; SARS‐CoV2, severe acute respiratory syndrome coronavirus‐2.